Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: Comment

Dear Editor,

We would like to share ideas on the publication “Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: a real-life study.¹” Meijide Mguez et al. describe the COVID-19 vaccine immunogenicity, efficacy, and reactogenicity after complete immunization (two doses), as well as immunogenicity and reactogenicity after one booster, in healthy NH workers and elderly residents in real-world settings.¹

After receiving the initial shot and the booster, Meijide Mguez et al. discovered evidence of cellular immunity. Moreover, one resident of the study was admitted to the hospital with SARS-CoV-2. The majority of adverse effects were moderate, and no deaths associated with SARS-CoV-2 were documented.¹ The BNT162b2 mRNA COVID-19 vaccine is immunogenic, efficient, and safe in elderly NH inhabitants with underlying chronic illnesses, according to Meijide Mguez et al.¹

To completely comprehend the outcomes, a number of things need to be examined. Without using specific laboratory testing, it is impossible to make a relationship between asymptomatic COVID-19 and the absence of symptoms. Asymptomatic COVID-19 and the absence of clinical symptoms could be misdiagnosed without comprehensive laboratory testing. If neither the most recent clinical signals nor the most recent clinical markers are present, a silent COVID-19 must be ruled out.² Some people's immune systems appear to respond to COVID-19 differently because of additional genetic differences.³ Further clinical research is required before the findings can be validated.

Data availability statement

There is no new data generated.

Funding

None.

Conflict of interest

None.